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Th-1 cellsStable isotope labeling by amino acid-based high-resolution phosphoproteomics is a powerful
technique that allows for direct comparison of cells stimulated under different experimental
conditions. This feature makes it the ideal methodology to identify cytokine signaling networks.
Here, we present an optimized protocol for the isolation and identification of phosphopeptides
from IL-6-stimulated primary human Th-1 cells.Martinez-Fabregas et al., STAR
Protocols 2, 100417
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https://doi.org/10.1016/j.xpro.2021.100417SUMMARY
Stable isotope labeling by amino acid-based high-resolution phosphoproteomics
is a powerful technique that allows for direct comparison of cells stimulated
under different experimental conditions. This feature makes it the ideal method-
ology to identify cytokine signaling networks. Here, we present an optimized
protocol for the isolation and identification of phosphopeptides from IL-6-stim-
ulated primary human Th-1 cells.
For complete details on the use and execution of this protocol, please refer to
Martinez-Fabregas et al. (2020).
BEFORE YOU BEGIN
This protocol describes the steps required for the isolation of phosphopeptides and for phospho-
proteomics analysis in human primary T cells from healthy donors. Three different populations of
T cells are generated by labeling themwith light, medium, and heavy SILAC amino acids. This allows
for side-by-side comparison of up to three different experimental conditions. All the work must be
carried out in a Cat II hood. Cat II containers need to be ready to dispose of the blood residue and a
1% Virkon solution must be used to decontaminate all the materials that get in contact with the
blood during the isolation of the cells.
KEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Rat anti-human-CD4-FiTC (clone A161A1) BioLegend Cat#357406; RRID: AB_2562357
Anti-FiTC microbeads Miltenyi Cat#130-048-701; RRID:AB_244371
Rat purified NA/LE anti-human-IL4
(clone MP4-25D2)







Chemicals, peptides, and recombinant proteins
Recombinant human interleukin-2 Novartis Cat#709421





purified in the lab
N/A
(Continued on next page)
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Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
ImmunoCult Human CD3/CD28 T
Cell Activator
STEMCELL Cat#10971
L-Lysine K0 Sigma Cat#L8662
L-Arginine R0 Sigma Cat#A8094
L-Proline P0 Sigma Cat#P0380
L-Lysine U-13C6 K6 CKGAS Cat##CLM-2247-0.25
L-Arginine U-13C6 R6 CKGAS Cat#CLM-2265-0.25
L-Lysine U-13C6,U-15N2 K8 CKGAS Cat#CNLM-291-H-0.25
L-Arginine U-13C6,U-15N2 R10 CKGAS Cat#CNLM-539-H-0.25
RPMI SILAC media Thermo Scientific Cat#88365
Dialyzed FBS HyClone Cat#SH30079.03
L-Glutamine Invitrogen Cat#25030024
Pen/Strep Invitrogen Cat#15140122
MEM vitamin solution Thermo Scientific Cat#11120052
Selenium-transferrin-insulin Thermo Scientific Cat#41400045
Triethylammonium bicarbonate buffer Thermo Scientific Cat#90114
Sodium dodecyl sulfate Sigma Cat#71725
Dithiothreitol Sigma Cat#D0632
Iodoacetamide Sigma Cat#I6125
Trypsin Thermo Scientific Cat#90058
Trifluoroacetic acid LC-MS grade Thermo Scientific Cat#85183
Acetonitrile LC-MS grade Thermo Scientific Cat#51101
MagResyn Ti-IMAC 2BScientific Cat#MR-TIM002
Ammonium hydroxide solution Sigma Cat#09859
Glycolic acid Sigma Cat#124737
Lymphoprep STEMCELL Cat#07801
LS columns Miltenyi Cat#130-042-401
QuadroMACS separator Miltenyi Cat#130-091-051
Critical commercial assays
BCA Protein Assay Kit Thermo Scientific Cat#23227
Quantitative Colorimetric Peptide Assay Thermo Scientific Cat#23275
Deposited data
Phosphoproteomics raw and analyzed data Martinez-Fabregas et al., 2020 ProteomeXchange: PXDX020964
Software and algorithms
MaxQuant Cox and Mann, 2008 https://www.maxquant.org
Andromeda Cox et al., 2011 https://www.maxquant.org
DAVID GO analysis tools Huang et al., 2007;
Huang da et al., 2009
https://david.ncifcrf.gov/home.jsp
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OPEN ACCESS ProtocolMATERIALS AND EQUIPMENT
CRITICAL: Trifluoroacetic acid (TFA) is harmful when inhaled and is toxic to aquatic life. Itneeds to be used in an extraction hood to minimize the risk of inhalation and needs to be
disposed following the appropriate health and safety regulations.STEP-BY-STEP METHOD DETAILS
Peripheral blood mononuclear cell (PBMC) isolation
Timing: 3 h
1. Blood donated by healthy donors was obtained from the Blood Transfusion Unit (Ninewells Hos-
pital, Dundee, UK) already in blood transfusion bags (Figure 1). Cut the lower tube of the bag con-
taining the blood samples. Make sure it is properly introduced in a 50 mL Falcon tube to avoid2 STAR Protocols 2, 100417, June 18, 2021
Figure 1. Blood transfusion bag scheme showing the upper and lower tubes for clarity
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OPEN ACCESSProtocolspillage of the blood and then cut the upper tube. Distribute the 50 mL of blood between two
clean, sterile 50 mL Falcon tubes (25 mL in each tube).
2. Add 25 mL of RPMI-1640 media without additives to each tube.
3. In 50 mL Falcon tubes add 25 mL of sterile Lymphoprep and slowly layer 25 mL of 1:2 diluted
blood on top of the Lymphoprep layer.
Note: Lymphoprep is a commercial density gradient medium recommended for the isolation
of mononuclear cells from peripheral blood. Alternatively, Ficoll gradients can also be used for
the isolation of lymphocytes (Corkum et al., 2015).
CRITICAL: Special care is needed not to mix the Lymphoprep-Blood layers to get PBMCsclear of red blood cells. For that, use an electronic pipette controller with a 25 mL pipette.STAR Protocols 2, 100417, June 18, 2021 3
Figure 2. Schematic representation of the Blood-Lymphoprep layer preparation
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OPEN ACCESS ProtocolCarefully put the tip of the 25 mL pipette containing 25 mL of blood in touch with the Lym-
phoprep layer and slowly add the blood on top (Please refer to Figure 2).4. Spin tubes at 800 g in a swing-bucket rotor centrifuge for 30 min at 18C–25C with maximum
acceleration but with no brake.
5. Collect the white buffy coat layer that forms an interface between the plasma layer above and the
red blood cells below into a clean, sterile 50 mL Falcon tube using sterile pastettes.
6. Wash the cells with 50 mL RPMI-1640 without additives and spin cells down cells by centrifuga-
tion: 5 min at 300 g maximum acceleration and maximum deceleration.
7. Repeat step 6 again.
8. Finally, resuspend the pellet in 50 mL of RPMI-1640 supplemented with 100 Units/mL Penicillin/,
100 mg/mL Streptomycin and 2 mM L-Glutamine.
9. Count the number of cells in a Flow cytometer gating on the lymphocytes based on their forward
scatter (FSC) and side scatter (SSC) profile (Figure 3). Dilute 10 mL of the cell suspension obtained4 STAR Protocols 2, 100417, June 18, 2021
Figure 3. Lymphocytes gating using the forward and side scatter profile
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OPEN ACCESSProtocolin step 8 in 490 mL RPMI (1:50 dilution) and count cells in the Flow cytometer for 60 s at a flow rate
of 1 mL/s. Using the number of lymphocytes (Figure 2) counted in 60 s (60 mL) calculate the total
number of lymphocytes in the 50 mL of sample obtained in step 8 taking into account the 1:50
dilution factor.Human primary CD4+ T cells isolation
Timing: 3 h
10. Transfer 108 lymphocytes into a new 50mL Falcon tube and spin them down by centrifugation at
300 g for 5 min.
11. Resuspend cells in 10 mL of sterile PBS supplemented with 0.5% BSA and 2 mM EDTA (PBE
buffer).
12. Collect cells again by centrifugation at 300 g for 5 min.
13. Resuspend the cells in 500 mL PBE buffer (sterile PBS supplemented with 0.5% BSA and 2 mM
EDTA), transfer to a 15 mL Falcon tube and stain them with 30 mL of anti-CD4-FiTC antibody
at +4C for 15 min.
14. Transfer 10 mL of stained cells into a 96 well V-bottom plate. This will be your pre-elution sample
that will allow you to calculate the total number of positive CD4 T cells in the cell suspension and
the efficiency of isolation.
15. Spin down cells in the Falcon tube at 300 g for 5 min at +4C.
16. Repeat the PBE wash again to remove unbound antibody.
17. Resuspend the cells in 500 mL PBE buffer and add 50 mL of anti-FiTC microbeads.
18. Incubate the cells at +4C for 15 min.
19. Resuspend the cells in 10 mL of PBE buffer and spin them down at 300 g for 5 min at +4C.
20. Repeat step 19 twice to remove the excess of unbound microbeads.
21. Equilibrate an LS column on a QuadroMACS separator with 3 mL of PBE.
22. Resuspend the cell pellet in 3 mL of PBE buffer and proceed to the isolation of CD4 stained cells
by Magnetic Activated Cell Sorting using the previously equilibrated LS column using a
QuadroMACS separator.STAR Protocols 2, 100417, June 18, 2021 5
Table 1. Preparation of SILAC amino acids stock solutions
Amino acid Molecular weight Stock (M) Stock (1/1000)
Light L-Lysine (K0) 182 0.219 40 mg/ml
Light L-Arginine (R0) 174.2 0.48 84 mg/ mL
Medium L-Lysine 13C6 (K6) 225.1 0.219 49 mg/mL
Medium L-Arginine 13C6 (R6) 126.6 0.48 103 mg/mL
Heavy L-Lysine 13C6,15N2 (K8) 227.1 0.219 49.7 mg/mL
Heavy L-Arginine 13C6,15N4 (R10) 220.59 0.48 105.8 mg/mL
Light L-Proline (P0) 115.13 1.7 200 mg/ml
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OPEN ACCESS Protocol23. After loading the cells onto the column wash the column three times with 3 mL of PBE buffer.
Collect the eluates from the three washes plus the eluate after loading your cells as your flow-
through samples. Transfer 10 mL of the flow-through into a 96 well V-bottom plate to check
the efficiency of isolation at the end of the procedure.
24. Finally, remove the LS column containing the CD4 stained cells from the separator and place it
into a 15 mL Falcon tube
25. Add 5 mL of PBE buffer and immediately flush out the CD4 positive T cells by firmly applying the
plunger supplied with the LS column. This sample contains the CD4+ T cells. Transfer 10 mL of
the flow-through into a 96 well V-bottom plate.
26. In the 96 well plate containing 10 mL from each sample add another 190 mL to dilute the samples
(1:20) and count cell in a flow cytometer to check the efficiency of isolation and to determine the
number of CD4+ T cells recovered at the end of the procedure. Add 190 mL of PBE to the 10 mL of
samples in the 96 well plate (1:20 dilution) and count cells in a flow cytometer to check the ef-
ficiency of isolation and to determine the number of CD4+ T cells recovered at the end of the
procedure.
Note: Usually starting with 108 lymphocytes, ~25–30 3 106 CD4+ T cells with a purity greater
than 95% should be recovered.Activation and SILAC labeling of cells
Timing: 10–14 days
27. Resuspend 107 CD4+ T cells in 5 mL of RPMI-1640 supplemented with Pen/Strep and L-Gluta-
mine and activate them for three days in the presence of 300 mL ImmunoCult Human CD3/CD28
T cell Activator and 20 ng/mL IL-2 under Th1 polarizing conditions: 20 ng/mL IL-12 and
10 ng/mL anti-IL-4.
28. After three days spin down cells at 300 g for 5 min and resuspend them in 10mL of light, medium
or heavy SILAC RPMI-1640 medium (please refer to Tables 1 and 2 in the materials and equip-
ment section) supplemented with 20 ng/mL IL-2, 20 ng/mL IL-12 and 10 ng/mL anti-IL4.
Note: Prepare amino acids stock solutions in newly opened, sterile PBS and store 0.5 mL
aliquots at 20C. Each aliquot is enough to prepare 500 mL of complete SILAC medium.
Note: SILACmedia for T cells is supplemented with light Proline as T cells can convert arginine
into proline affecting the labelling, so by increasing the concentration of proline we block this
pathway.
Note: After combining all the reagents required for the preparation of SILAC media filter the
media using a 500 mL Stericup Filtration System and keep the media at +4C.6 STAR Protocols 2, 100417, June 18, 2021








SILAC RPMI-1640 media 500 mL 500 mL 500 mL
Dialyzed SILAC-grade FBS 50 mL 50 mL 50 mL
L-Glutamine 1003 5 mL 5 mL 5 mL
Penicillin/Streptomycin 1003 5 mL 5 mL 5 mL
MEM vitamin solution 1003 5 mL 5 mL 5 mL
Sodium pyruvate 1003 5 mL 5 mL 5 mL
Selenium, Transferrin & Insulin 1003 5 mL 5 mL 5 mL
Light L-Lysine (K0) stock 13 0.5 mL aliquot
Light L-Arginine (R0) stock 13 0.5 mL aliquot
Medium L-Lysine 13C6 (K6) stock 13 0.5 mL aliquot
Medium L-Arginine 13C6 (R6) stock 13 0.5 mL aliquot
Heavy L-Lysine 13C6,15N2 (K8) stock 13 0.5 mL aliquot
Heavy L-Arginine 13C6,15N4 (R10) stock 13 0.5 mL aliquot
Light L-Proline (P0) 13 0.5 mL aliquot 13 0.5 mL aliquot 13 0.5 mL aliquot
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OPEN ACCESSProtocol29. Count the number of cells every two-three days and dilute them down to 106 cells / mL. Keep
them growing in the appropriate SILAC media (light, medium or heavy) supplemented with
IL-2, IL-12 and anti-IL-4 for 5 cell division cycles to ensure complete labeling.Preparation of sample for proteomics
Timing: 2–3 days
30. Count cells in a flow cytometer and collect about 108 cells per SILAC labeling (light, medium or
heavy) by centrifugation at 300 g for 5 min. Transfer them into a clean T175 flask containing
25 mL of the appropriate SILAC media without IL-2 and starve the cells for 24 h. Alternatively,
at this stage cell counting could be done using standard cell counting practices, such as count-
ing slides.
Note: Cells are starved of cytokines (IL-2, IL-4 and IL-12) for 16 h before stimulation to reduce
the basal levels of the signaling pathways engaged by IL-2, IL-4 and IL-12. This step allows us
to reduce the confounding effects of having IL-2, IL-4 and IL-12 present during the stimulation
with the cytokine of interest (i.e., IL-6 in this study).
31. Next day collect cells again by centrifugation, resuspend them in SILAC RPMI-1640 media con-
taining FBS and stimulate them as required. In our case cells were treated as follows:a. T cells grown in light SILAC media were unstimulated and used as a reference control.
b. T cells grown in medium SILAC media were stimulated with 20 nM IL-6 for 15 min.
c. T cells grown in heavy SILACmedia were treated with 2 mM of MSC2530818, a specific CDK8
inhibitor, for 30 min and then stimulated with 20 nM IL-6 for 15 min.32. After stimulation, wash cells three times with 50 mL of ice cold PBS, then combine in a 1:1:1
(light : medium : heavy) ratio.
Note: It is important to check for the label incorporation efficiency. To do so, collect about 106
cells labelled with the different amino acids (light, medium, and heavy) and transfer them into
a clean, low protein bindingmicrocentrifuge tube. Follow the same protocol described below,
just adjusting the volumes as required and analyze the peptides to determine the percentage
of labelling of the different samples. At least, 95% labelling efficiency is required.STAR Protocols 2, 100417, June 18, 2021 7
Table 3. Buffers required for the phosphopeptide enrichment and purification
Reagent Composition
Loading buffer 0.1 M glycolic acid in 80% acetonitrile (ACN) and 5% trifluoroacetic
acid (TFA)
Wash buffer 1 80% ACN, 1% TFA in mass spectrometry grade H2O
Wash buffer 2 10% ACN, 0.2% TFA in mass spectrometry grade H2O
Elution buffer 1% NH4OH
All these buffers should be freshly made.
ll
OPEN ACCESS ProtocolNote: Light, medium and heavy SILAC labels are mixed at this point in order to avoid differ-
ences arising from the manipulation of the samples during cell lysis, protein precipitation and
digestion, peptide fractionation and enrichment.
33. After the final wash, resuspend the cell pellet (1 volume) in SDS-lysis buffer (5 volumes) and incu-
bate on ice for 10 min to ensure complete cell lysis.
Note: SDS-containing lysis buffer should be freshly prepared by dissolving SDS (1% w/v) in
100 mM Triethylammonium Bicarbonate Buffer (TEAB) pH8.
34. Centrifuge the cell lysates at 20,000 g for 15 min at +4C and transfer supernatants to clean Fal-
con tubes.
35. Determine protein concentrations using a BCA Protein Assay kit.
36. Transfer 10 mg of total protein per experiment of combined light, medium, and heavy labeled
proteins into a clean, low protein binding microcentrifuge tube and reduce the protein sample
with 10 mM dithiothreitol for 1 h at 55C in order to break all disulfide bridges and linearize the
proteins.
37. Alkylate the protein sample with 20 mM iodoacetamine for 30 min at 18C–25C in order to
block the free cysteine residue and avoid the formation of new disulfide bridges.
38. Finally, precipitate the proteins using six volumes of chilled (20C) acetone for 16 h at 20C.
39. After precipitation, protein pellets were obtained by centrifugation at 14,000 g for 30 min
at +4C . Then, resuspend protein pellet (10 mg) in 1 mL of 100 mM TEAB and digest with
100 mg of Trypsin (1:100 w/w) for 16–24 h at 37C. Digestion was done in two steps. First add
50 mg of Trypsin to the protein suspension and incubate for 2 h. Then, add the remaining
50 mg of Trypsin and digest the protein for 16–24 h at 37C in a thermoblock with shaking at
1000 rpm.
Note: After resuspension in 1 mL of 100 mM TEAB the protein suspension can look cloudy as
proteins will not be completely in solution. This is normal and the protein solution will become
clear during protein digestion.
Note: Trypsin purchased from Thermo in 100 mg vials was reconstituted using 50 mM acetic
acid to (1 mg / mL) (i.e., add 100 mL of 50 mM acetic acid to 100 mg of lyophilized Trypsin).
40. After protein digestion, clear the samples by centrifugation at 20,000 g for 30 min at +4C, and
determine the peptide concentration using a Quantitative Colorimetric Peptide Assay.
41. Lyophilize 3.5 mg of peptides per sample (already containing the light, medium, and heavy pep-
tides) using an EZ-2 Plus Centrifugal Evaporator (GeneVac, HPLC program, 40 h, 40C).Peptide fractionation
Timing: 5–6 h per sample8 STAR Protocols 2, 100417, June 18, 2021
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OPEN ACCESSProtocolNote: This step is not required to determine the labelling incorporation efficiency, so samples
prepared to check this can be already analyzed by mass spectrometry and .RAW files analyzed
by MaxQuant (see below).
42. Resuspend the lyophilized peptide samples in 200 mL Buffer A (10 mM ammonium formate), trap
them on a XBridge trap cartridge (Waters, C18, 3.5 mM, 4.6 3 20 mm) and separate them on a
XBridge Peptide BEH column (Waters, C18, 3.5 mM, 4.6 3 250 mm) using an Ultimate 3000
RSLCnano system (Thermo Scientific). Resolve peptides using a gradient (102 min, 0.8 mL/min)
of Buffer A (10 mM ammonium formate) and Buffer B (10 mM ammonium formate, 90% aceto-
nitrile): 8% Buffer B for 16 min, 8%–45% Buffer B for 54 min, 45%–100% Buffer B for 5 min, 100%
Buffer B for 16 min and 100%–2% Buffer B for 21 min.
43. Collect 80 fractions of 0.8 mL each (1 min) using a WPS-3000FC autosampler (Thermo Scientific)
from 1 to 80 min over the chromatogram.
44. Concatenate fractions to 20 fractions to provide a similar quantity of peptide per fraction based
on the online (U3000 Variable Wavelength Detector, Thermo Scientific) UV values of the eluted
peptides at 200 nm.
45. Dry fractions (EZ-2 Plus Centrifugal Evaporator, GeneVac) prior to phosphopeptide enrichment.Phosphopeptide enrichment
Timing: depends on the number of samples to be processed; in our case 2–3 days
Note: Buffers required for phosphopeptide enrichment and purification are described in Table 3.
46. For phosphopeptide enrichment, use 50 mL (1 mg of beads) of MagResyn Ti-IMAC beads per
sample to ensure complete depletion of phosphopeptides. Phosphopeptide enrichment could
be done using an automatic processing pipeline (Tape et al., 2014).
47. For this protocol 60 fractions of peptides (20 fractions per replica) were being used. Thus, trans-
fer 3 mL of MagResyn (50 mL per sample) into 2 mL clean low protein binding microcentrifuge
tube (1.5 mL per tube).
48. Place tubes in a magnetic separator, and after 10–20 s remove the solution.
49. Resuspend particles in 2 mL of Loading buffer and allow 1 min for equilibration.
50. Place tubes back in the magnetic separator allowing 10–20 s for microparticles to clear. Then,
remove the loading buffer.
51. Repeat steps 49 and 50 three more times.
52. After the last step of equilibration distribute microparticles into 60 1.5 mL clean, low protein
binding microcentrifuge tubes.
53. Place tubes in a magnetic separator and remove supernatant. Microparticles are now ready for
the phosphopeptide enrichment procedure.
54. Resuspend each peptide fraction in 100 mL of loading buffer and vortex to allow complete resus-
pension of the peptides.
55. Centrifuge samples for 10 min at 15000 g to remove insoluble material and transfer the super-
natant into 1.5 mL clean, low protein binding microcentrifuge tubes containing the MagResyn
Ti-IMAC microparticles, resuspending the microparticles by vortexing samples for 10 s.
56. Incubate the peptide – microparticles mixture for 20 min at 18C–25C with continuous mixing.
CRITICAL: In order to optimize the binding of the phosphopeptides to the TiO2 micropar-ticles it is essential to apply continuous mixing (every 2–3 min, slow vortexing) during the
incubation at 18C–25C.57. Place the tube on the magnetic separator, allow 10–20 s for the magnetic beads to separate.
Remove and discard the supernatant.STAR Protocols 2, 100417, June 18, 2021 9
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OPEN ACCESS ProtocolNote: This supernatant should contain unbound, non-phosphorylated peptides.
58. Wash the microparticles with 100 mL of loading buffer for 2 min with gentle shaking in order to
remove unbound peptides. After this, place the tubes again in the magnetic separator and once
the microparticles have cleared remove and discard the supernatant.
59. Wash the microparticles with 100 mL of Wash buffer 1 for 2 min with gentle shaking in order to
remove peptides bound non-specifically.
60. Remove the supernatant by placing the tubes back in the magnetic separator and allow 10–20 s
for the magnetic microparticles to clear.
61. Repeat steps 59 and 60 for an additional wash discarding the supernatant after every wash.
62. Wash the microparticles for 2 min with 100 mL of Wash buffer 2. After incubation place the tubes
back in the magnetic separator, remove, and discard the supernatant.
63. Resuspend the magnetic microparticles with 150 mL of Elution buffer and incubate for 10 min at
18C–25C to allow the elution of the phosphopeptides.
CRITICAL: In order to optimize the elution of the phosphopeptides from the magnetic mi-croparticles it is essential to ensure the microparticles remain in suspension by constant
gentle agitation in a shaker at 1000 rpm during the elution.64. Recover the phosphopeptides in suspension by placing the tubes in the magnetic separator for
10 s to allow the magnetic microparticles to clear. After this, transfer the supernatant (eluted
phosphopeptides) to a clean 1.5 mL protein low protein binding microcentrifuge tube with
50 mL of formic acid 10%.
65. To maximize phosphopeptide recovery repeat the elution steps 62 and 63 with another 150 mL
of Elution buffer.
66. Place the tubes again in the magnetic separator, allow 20 s for microparticles to clear and pool
the supernatant with the previously eluted phosphopeptides, adding a further 50 mL of 10% for-
mic acid for a total volume of 400 mL.
67. Vacuum dry the eluates using an EZ-2 Plus Centrifugal Evaporator (GeneVac, HPLC program, 40
h, 40C).
Mass spectrometry analysis of phosphopeptides
Timing: depends on the number of samples to be processed; in our case 1 week
68. Phosphopeptide samples were analyzed using a nanoflow liquid chromatography system (Ulti-
mate 3000 RSLCnano, Thermo Scientific) coupled to a Q Exactive Plus Mass Spectrometer
(Thermo Scientific).
Note: Mass spectrometry analysis can be carried out using different system (e.g., Q Exactive
HF, LTQ Orbitraps, etc)
69. Phosphopeptide samples (10 mL) were loaded onto a C18 trap column and washed for 5min with
0.1% formic acid.
70. Phosphopeptides were resolved using a gradient (170 min, 0.3 mL/min) of Buffer A (0.1% formic
acid) and Buffer B (80% acetonitrile in 0.08% formic acid): 5% Buffer B for 5min, 5%–35%Buffer B
for 125min, 35%–98% Buffer B for 2 min, 98% Buffer B for 20min, 98%–2% Buffer B for 1 min and
2% Buffer B for 17 min.
71. Phosphopeptides, initially trapped in an Acclaim PepMap 100 C18 column (100 mm x 2 cm,
Thermo Scientific), were separated on an Easy-Spray PepMap RSLC C18 column (75 mm x
50 cm, Thermo Scientific)
72. Finally, the phosphopeptides were transferred to a Q Exactive Plus Mass Spectrometer via and
Easy-Spray source with temperature set at 50C and a source voltage of 0.2 kV.10 STAR Protocols 2, 100417, June 18, 2021
ll
OPEN ACCESSProtocol73. Peptides were identified with a top 15 method (1 MS plus 15 MS2, 150 min acquisition) consist-
ing of full scans and mass range (m/z) between 350 to 1600 (m/z) for MS search and 200 to 2000
(m/z) for MS2 search.
74. For the MS2 scan the Q Exactive Plus Mass Spectrometer was operated in a data dependent
acquisition mode, resolution of 70,000 with a lock mass set at 445.120024 and max fill time of
20 ms.
75. For the MS2 scan the Q Exactive Pluss Mass Spectrometer was operated in a centroid mode, res-
olution of 15,000 with isolation window = 1.4 (m/z), normalized collision energy = 27, max fill
time of 100 ms and dynamic exclusion of 45 s.Analysis of mass spectrometry raw files
Timing: depends on the number of samples to be processed; in our case 1–2 week
76. Q Exactive Plus Mass Spectrometer .RAW files were analyzed and phosphopeptides identified
and quantified using MaxQuant software (Cox and Mann, 2008), utilizing the built-in search en-
gine Andromeda (Cox et al., 2011).
Note: There are available different proteomic software for phosphopeptide identification and
quantitation (e.g., PEAKS (Bioinformatics Solutions), Proteome Discoverer (Thermo), Scaffold
(Proteome Software)).
77. All settings were set as default, except for minimal peptide length of 5, and the Andromeda
search engine was configured for the Uniprot Homo sapiens database (release date: 2018_09).
78. Only phosphopeptides quantified in at least two out of three replicates were considered, and
the p values were determined by Student’s t test corrected for multiple testing using the
Benjamini–Hochberg procedure (Benjamini and Hochberg, 1995).
79. GO analysis were carried out using DAVIDGO analysis tools (Huang da et al., 2009; Huang et al.,
2007).EXPECTED OUTCOMES
Upon activation and expansion of 107 CD4+ T cells in SILAC media for 5 cell division cycles more
than 108 SILAC-labeled cells should be recovered. Upon stimulation with the different experimental
conditions we only combined 108 cells per condition (light, medium, and heavy SILAC labeling) as
those cell numbers (3 3 108 total cells) should render enough protein (roughly 30 mg of protein)
to repeat the experiment if something fails. After protein reduction with 10 mM DTT and alkylation
with 20 mM iodoacetamide protein was precipitated for 16 h with six volumes of chilled acetone at
20C. After protein precipitation, the protein pellet can be easily resuspended in 1 mL of 100 mM
TEAB although it will appear cloudy. This is to be expected as proteins do not completely go into
solution. The protein suspension will become clear upon digestion with Trypsin.After protein diges-
tion the quantification of peptide concentration in all the samples is recommended before proceed-
ing to peptide fractionation, phosphopeptide enrichment, and mass spectrometry analysis. In our
hands, after protein precipitation and digestion we were able to recover about 7 mg of peptides
that were then used for peptide fractionation into 20 individual fractions each of them containing
roughly 350 mg of peptides. These peptide fractions were used for phosphopeptide enrichment
then were analyzed by mass spectrometry and finally quantified using MaxQuant (Cox and Mann,
2008; Cox et al., 2011). This experimental approach normally allows for the identification and quan-
tification of roughly 20,000 unique phosphopeptides.LIMITATIONS
SILAC-based proteomic and phosphoproteomic studies relies on the complete incorporation of the
SILAC amino acids into the proteins (Mann, 2006; Ong et al., 2002). For that reason, cells need toSTAR Protocols 2, 100417, June 18, 2021 11
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OPEN ACCESS Protocolproliferate and divide for at least 3 cell division cycles, somehow limiting the application of SILAC
based proteomics and phosphoproteomic studies to cell types that can be expanded in vitro in
SILAC media. Thus, checking the labeling incorporation is essential in order to guarantee
the success of the study. If complete labeling cannot be achieved, then alternative methods
(e.g., label-free or TMT-labeling techniques) (Kauko et al., 2015; Navarrete-Perea et al., 2018;
Zecha et al., 2019; Zhang et al., 2015) need to be used. Additionally, due to the high number of




A low number of lymphocytes (less than 108) were obtained after PBMCs isolation.
Potential solution
Make sure that the white buffy coat layer is completely collected to maximize the recovery PBMCs
(step 5). However, sometimes this is due to poor quality of the blood sample obtained (e.g., not a
fresh sample of blood). In these circumstances a new, fresh sample of blood is required to start
the protocol again.
Problem 2
A low number of CD4+ T cells were obtained after isolation (Step 26).
Potential solution
Check your flow-through samples for the presence of unbound FiTC-positive CD4+ T cells. If this
happens add another 50 mL of anti-FiTC microbeads and repeat the elution again to recover all
the FiTC-positive CD4+ T cells.
If the flow-through is depleted of FiTC-positive CD4+ T cells start from a larger number of
lymphocytes.
Problem 3
Purity of Isolated CD4+ T cells was less than 95% (Step 26).
Potential solution
Increase the number of washes with 3 mL of PBE buffer before the elution step.
Problem 4
SILAC labeling checks show an amino acid labeling incorporation less than 95% (Step 31).
Potential solution
Even though 5 cell division cycles should give a labeling incorporation efficiency greater that 98%–
99%, if labeling incorporation is smaller than 95%, CD4+ T cells can be kept growing in SILACmedia
for an extra cell division cycle.
Problem 5
Low recovery or low signal after phosphopeptide enrichment.
Potential solutions
Low recovery of phosphopeptides (Step 63) during the phosphopeptide enrichment could be due to
the use of a incorrect elution buffer. Make sure the concentration of NH4OH is 1%. Also the elution of
phosphopeptides can be maximized by increasing the volume of elution buffer used or alternatively
by increasing the number of elution steps. Low signal of phosphopeptides (Step 68) can be solved by




Further information and requests for resources and reagents should be directed to and will be ful-
filled by the lead contact Ignacio Moraga Gonzalez (imoragagonzalez@dundee.ac.uk).
Materials availability
This study did not generate new unique reagents.
Data and code availability
The datasets generated during this study have been deposited in the ProteomeXchange:
PXD020964 and are described in (Martinez-Fabregas et al., 2020).
ACKNOWLEDGMENTS
This work was supported by the Wellcome Trust 202323/Z/16/Z and ERC-2060STG (I.M.). We would
like to thank the Fingerprints Proteomics Facility (University of Dundee) for the mass spectrometry
analysis of the samples
AUTHOR CONTRIBUTIONS
J.M.-F., E.P., and I.M. conceived the project; J.M.-F., E.P., and I.M. wrote the manuscript; J.M.-F.
performed phosphoproteomics studies.
DECLARATION OF INTERESTS
The authors declare no competing interests.REFERENCESBenjamini, Y., and Hochberg, Y. (1995). Controlling
the False Discovery Rate - a Practical and Powerful
Approach to Multiple Testing. J. R. Stat. Soc. Ser. B
Stat. Methodol. 57, 289–300.
Corkum, C.P., Ings, D.P., Burgess, C.,
Karwowska, S., Kroll, W., and Michalak, T.I.
(2015). Immune cell subsets and their gene
expression profiles from human PBMC isolated
by Vacutainer Cell Preparation Tube (CPT)
and standard density gradient. BMC Immunol.
16, 48.
Cox, J., and Mann, M. (2008). MaxQuant enables
high peptide identification rates, individualized
p.p.b.-range mass accuracies and proteome-wide
protein quantification. Nat. Biotechnol. 26, 1367–
1372.
Cox, J., Neuhauser, N., Michalski, A., Scheltema,
R.A., Olsen, J.V., andMann, M. (2011). Andromeda:
a peptide search engine integrated into the
MaxQuant environment. J. Proteome Res. 10,
1794–1805.
Huang da, W., Sherman, B.T., and Lempicki, R.A.
(2009). Systematic and integrative analysis of large
gene lists using DAVID bioinformatics resources.
Nat. Protoc. 4, 44–57.Huang, D.W., Sherman, B.T., Tan, Q., Collins, J.R.,
Alvord, W.G., Roayaei, J., Stephens, R., Baseler,
M.W., Lane, H.C., and Lempicki, R.A. (2007). The
DAVID Gene Functional Classification Tool: a
novel biological module-centric algorithm to
functionally analyze large gene lists. Genome
Biol. 8, R183.
Kauko, O., Laajala, T.D., Jumppanen, M.,
Hintsanen, P., Suni, V., Haapaniemi, P., Corthals,
G., Aittokallio, T., Westermarck, J., and Imanishi,
S.Y. (2015). Label-free quantitative
phosphoproteomics with novel pairwise
abundance normalization reveals synergistic RAS
and CIP2A signaling. Sci. Rep. 5, 13099.
Mann, M. (2006). Functional and quantitative
proteomics using SILAC. Nat. Rev. Mol. Cell Biol. 7,
952–958.
Martinez-Fabregas, J., Wang, L., Pohler, E.,
Cozzani, A.,Wilmes, S., Kazemian,M.,Mitra, S., and
Moraga, I. (2020). CDK8 fine-tunes IL-6
transcriptional activities by limiting STAT3 resident
time at the gene loci. Cell Rep. 33, 108545.
Navarrete-Perea, J., Yu, Q., Gygi, S.P., and Paulo,
J.A. (2018). Streamlined tandemmass tag (SL-TMT)
protocol: an efficient strategy for quantitative
(Phospho)proteome profiling using tandem masstag-synchronous precursor selection-MS3.
J. Proteome Res. 17, 2226–2236.
Ong, S.E., Blagoev, B., Kratchmarova, I.,
Kristensen, D.B., Steen, H., Pandey, A., and Mann,
M. (2002). Stable isotope labeling by amino acids in
cell culture, SILAC, as a simple and accurate
approach to expression proteomics. Mol. Cell.
Proteomics. 1, 376–386.
Tape, C.J., Worboys, J.D., Sinclair, J., Gourlay, R.,
Vogt, J., McMahon, K.M., Trost, M., Lauffenburger,
D.A., Lamont, D.J., and Jorgensen, C. (2014).
Reproducible automated phosphopeptide
enrichment using magnetic TiO2 and Ti-IMAC.
Anal. Chem. 86, 10296–10302.
Zecha, J., Satpathy, S., Kanashova, T., Avanessian,
S.C., Kane,M.H., Clauser, K.R.,Mertins, P., Carr, S.A.,
and Kuster, B. (2019). TMT labeling for the masses: a
robust and cost-efficient, in-solution labeling
approach. Mol. Cell. Proteomics 18, 1468–1478.
Zhang, H., Sun, J., Ye, J., Ashraf, U., Chen, Z., Zhu, B.,
He, W., Xu, Q., Wei, Y., Chen, H., et al. (2015).
Quantitative label-free phosphoproteomics reveals
differentially regulated protein phosphorylation
involved inwest nile virus-inducedhost inflammatory
response. J. Proteome Res. 14, 5157–5168.STAR Protocols 2, 100417, June 18, 2021 13
